atripla - MSD Responsibility
Worldwide Marketing Authorization Status: ATRIPLA® Indication: HIV infection Approved 1. Aruba 2. Bolivia 3. Botswana 4. Burkina Faso 5. Cameroon 6. Central African Republic 7. Chad 8. Congo_Brazzaville 9. Congo-Kinshasa 10. Cote d'Ivoire 11. Dominican Republic 12. Ecuador 13. El Salvador
Approved 25. Namibia 26. Nicaragua 27. Nigeria 28. Panama 29. Peru 30. Senegal 31. South Africa 32. Tanzania 33. Togo 33. Trinidad and Tobago 34. Uganda 35. Ukraine 36. Zambia
Filed 1. Cape Verde 2. Djibouti 3. Guinea-Bissau 4. Rwanda 5. Syria 6. Trinidad
14. Equatorial Guinea 15. Ethiopia 16. Gabon 17. Ghana 18. Guatemala 19. Guinea 20. Honduras 21. Jamaica 22. Kenya 23. Malawi 24. Mozambique
Disclaimer: There can be no guarantee that marketing approval for ATRIPLA® will be granted in any of the countries where registration is pending, and any marketing approval, if granted, may have significant limitations on its use. Terms and Definitions Approved: Countries where the dossier has been submitted and approved. Filed: Countries where the dossier has been submitted and review is pending.
June 2016
Approved 25. Namibia 26. Nicaragua 27. Nigeria 28. Panama 29. Peru 30. Senegal 31. South Africa 32. Tanzania 33. Togo 33. Trinidad and Tobago 34. Uganda 35. Ukraine 36. Zambia
Filed 1. Cape Verde 2. Djibouti 3. Guinea-Bissau 4. Rwanda 5. Syria 6. Trinidad
14. Equatorial Guinea 15. Ethiopia 16. Gabon 17. Ghana 18. Guatemala 19. Guinea 20. Honduras 21. Jamaica 22. Kenya 23. Malawi 24. Mozambique
Disclaimer: There can be no guarantee that marketing approval for ATRIPLA® will be granted in any of the countries where registration is pending, and any marketing approval, if granted, may have significant limitations on its use. Terms and Definitions Approved: Countries where the dossier has been submitted and approved. Filed: Countries where the dossier has been submitted and review is pending.
June 2016
